Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1998-07-02
2000-08-15
Lee, Howard C.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
514810, 514885, 514886, 514909, 514925, A61K 3147
Patent
active
061037370
ABSTRACT:
Corticotropin releasing factor (CRF) antagonists of formula I: ##STR1## and their use in treating psychiatric disorders and neurological diseases, anxiety-related disorders, post-traumatic stress disorder, supranuclear palsy and feeding disorders as well as treatment of immunological, cardiovascular or heart-related diseases and colonic hypersensitivity associated with psychopathological disturbance and stress in mammals.
REFERENCES:
Petel, Journal of Geriatric Psychiatry and Neurology, vol. 8, 81-95, (1995).
Ehlert et al., Life Sciences, vol. 55, No. 25/26, 2135-2145, (1994).
Beck James P.
Cocuzza Anthony J.
Gilligan Paul J.
Hobbs Frank W.
DuPont Pharmaceuticals Company
Lee Howard C.
O'Brien Maureen P.
Rubin Kenneth B.
White Everett
LandOfFree
Aryl- and arylamino- substituted heterocycles as corticotropin r does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Aryl- and arylamino- substituted heterocycles as corticotropin r, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Aryl- and arylamino- substituted heterocycles as corticotropin r will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2007258